Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Drop in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 12,600 shares, a drop of 40.0% from the February 13th total of 21,000 shares. Based on an average trading volume of 81,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are short sold.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ:GNOM opened at $8.84 on Monday. The company’s fifty day moving average price is $9.69 and its 200 day moving average price is $10.31. Global X Genomics & Biotechnology ETF has a 12 month low of $8.59 and a 12 month high of $11.88. The firm has a market capitalization of $61.61 million, a P/E ratio of -3.78 and a beta of 1.03.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GNOM. Raymond James Financial Inc. purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at about $2,974,000. Portland Global Advisors LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 3.6% during the fourth quarter. Portland Global Advisors LLC now owns 268,988 shares of the company’s stock worth $2,612,000 after buying an additional 9,373 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 4.9% in the fourth quarter. Jane Street Group LLC now owns 133,405 shares of the company’s stock valued at $1,295,000 after purchasing an additional 6,221 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 74.5% in the fourth quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock valued at $830,000 after purchasing an additional 36,500 shares in the last quarter. Finally, Flow Traders U.S. LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $936,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.